DEUTSCHE BANK: Buy these 6 auto stocks in 2021 to capitalize on the rise of electric and self-driving cars

Financial world news, market analysis, investment scam prevention tips and more ✔️ Learn all there is to know about the asset management industry. This magazine is crafted specifically for those who are interested in diving into the global asset management world. Nio ES6. NIODeutsche Bank named its eight auto-industry stock picks for 2021 in a research note. Six could benefit from the rise of electric and autonomous vehicles. They are Tesla, GM, Luminar, Nio, Aptiv, and Visteon. Visit Business Insider's homepage for more stories. Automakers and tech companies have spent billions over the past decade preparing for a future dominated by electric cars and automated-driving technology.  When looking at the auto industry, investors should focus on how well companies are positioned to capitalize on those trends, according to Deutsche Bank analysts Emmanuel Rosner, Edison Yu, and Conor Walters, who shared their 2021 stock picks for the automotive industry in a January 20 research note. "We expect Autos 2.0 (electrification, autonomy, and connectivity) to remain the most powerful investment trends again this year," the analysts wrote. Six of the eight companies included in the analysts' 2021 picks have the potential to benefit from the shift to electric and increasingly automated vehicles, the analysts said. The analysts also picked two suppliers, Adient and Dana, that can make parts for electric or gas-powered vehicles and could benefit from improved demand for vehicles and additional fiscal stimulus measures. These are Deutsche Bank's automotive stock To keep reading about DEUTSCHE BANK: Buy these 6 auto stocks in 2021 to capitalize on the rise of electric and self-driving cars, Click on the link. Seoul, Korea
http://dlvr.it/RrBDsB

Comments

Popular posts from this blog

AstraZeneca Begins Phase I Trial Of AZD7442 Against COVID-19 – Quick Facts

Coronavirus Hasn't Diminished Tech Stocks' Allure

Henlius Plans to File the NDA of Novel anti-PD-1 mAb HLX10 for the Treatment of MSI-H Solid Tumours, the Phase 2 Clinical Trial has Met the Primary Endpoint